These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19174952)

  • 1. Proposal for a new categorization of aseptic processing facilities based on risk assessment scores.
    Katayama H; Toda A; Tokunaga Y; Katoh S
    PDA J Pharm Sci Technol; 2008; 62(4):235-43. PubMed ID: 19174952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Media-fill simulation tests in manual and robotic aseptic preparation of injection solutions in syringes.
    Krämer I; Federici M; Kaiser V; Thiesen J
    J Oncol Pharm Pract; 2016 Apr; 22(2):195-204. PubMed ID: 25549919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boundary and airlock design issues in aseptic facilities.
    Lorenz MR; Robinson JE
    J Parenter Sci Technol; 1991; 45(6):279-85. PubMed ID: 1802984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the BioVigilant IMD-A, a novel optical spectroscopy technology for the continuous and real-time environmental monitoring of viable and nonviable particles. Part II. Case studies in environmental monitoring during aseptic filling, intervention assessments, and glove integrity testing in manufacturing isolators.
    Miller MJ; Walsh MR; Shrake JL; Dukes RE; Hill DB
    PDA J Pharm Sci Technol; 2009; 63(3):259-83. PubMed ID: 20069799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Top ten hot topics in parenteral science and technology.
    Akers MJ; Nail SL; Saffell-Clemmer W
    PDA J Pharm Sci Technol; 2007; 61(5):337-61. PubMed ID: 18047174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous Microbiological Environmental Monitoring for Process Understanding and Reduced Interventions in Aseptic Manufacturing.
    Weber J; Hauschild J; Ijzerman-Boon P; Forng RY; Horsch J; Yan L; Prasad A; Henry RB; Claassen M; Villari P; Shereefa S; Wyatt J; Bolden JS; Pycke JT; Dassu D
    PDA J Pharm Sci Technol; 2019; 73(2):121-134. PubMed ID: 30361285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panel discussion: Environmental sampling in an aseptic environment. III. Cross contamination control.
    Elias WF
    Bull Parenter Drug Assoc; 1974; 28(6):263-9. PubMed ID: 4455322
    [No Abstract]   [Full Text] [Related]  

  • 8. Aseptic processing contamination case studies and the pharmaceutical quality system.
    Friedman RL
    PDA J Pharm Sci Technol; 2005; 59(2):118-26. PubMed ID: 15971544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous microbiological air monitoring for aseptic filling lines.
    Scherwing C; Golin F; Guenec O; Pflanz K; Dalmaso G; Bini M; Andone F
    PDA J Pharm Sci Technol; 2007; 61(2):102-9. PubMed ID: 17479718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous microbiological air monitoring for aseptic filling lines.
    Ginsbury K
    PDA J Pharm Sci Technol; 2007; 61(4):225. PubMed ID: 17933205
    [No Abstract]   [Full Text] [Related]  

  • 11. Current practice in the operation and validation of aseptic blow-fill-seal processes.
    Ljungqvist B; Reinmüller B; Löfgren A; Dewhurst E
    PDA J Pharm Sci Technol; 2006; 60(4):254-8. PubMed ID: 17089694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA's aseptic processing: proposed regulation.
    Barr DB
    J Parenter Sci Technol; 1993; 47(2):57-9. PubMed ID: 8515345
    [No Abstract]   [Full Text] [Related]  

  • 13. Microbiological validation of a robot for the sterile compounding of injectable non-hazardous medications in a hospital environment.
    Sabatini L; Paolucci D; Marinelli F; Pianetti A; Sbaffo M; Bufarini C; Sisti M
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e63-e68. PubMed ID: 32296508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
    Garcia FA; Vandiver MW
    PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panel discussion: environmental sampling in an aseptic environment. I. Microbiological environmental monitoring.
    Raiman HL
    Bull Parenter Drug Assoc; 1974; 28(6):253-60. PubMed ID: 4616742
    [No Abstract]   [Full Text] [Related]  

  • 16. Revision of Viable Environmental Monitoring in a Development Pilot Plant Based on Quality Risk Assessment: A Case Study.
    Ziegler I; Borbély-Jakab J; Sugó L; Kovács RJ
    PDA J Pharm Sci Technol; 2017; 71(3):234-244. PubMed ID: 28089966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk management, cGMP, and the evolution of aseptic processing technology.
    Agalloco J; Akers J; Baseman H; Boeh R; Madsen R; Ostrove S; Pavell A
    PDA J Pharm Sci Technol; 2009; 63(1):8-10. PubMed ID: 19455938
    [No Abstract]   [Full Text] [Related]  

  • 18. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In line validation of sanitizing agents in aseptic processing areas.
    Chesky SR
    J Parenter Sci Technol; 1986; 40(4):169-74. PubMed ID: 3095529
    [No Abstract]   [Full Text] [Related]  

  • 20. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.